96 related articles for article (PubMed ID: 9159336)
1. Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells.
Street D; Kaufmann AM; Vaughan A; Fisher SG; Hunter M; Schreckenberger C; Potkul RK; Gissmann L; Qiao L
Gynecol Oncol; 1997 May; 65(2):265-72. PubMed ID: 9159336
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic activity of NK cells against SW-756 squamous cervical carcinoma cell line: role of interferons alpha and gamma and CD54 adhesion molecule in oncolysis.
Cristoforoni PM; Lotzová E; Cook KR; Chuang LT; Morris M; Grossi CE; Wharton JT
Gynecol Oncol; 1994 Mar; 52(3):365-72. PubMed ID: 7512522
[TBL] [Abstract][Full Text] [Related]
3. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens.
Kaufmann AM; Gissmann L; Schreckenberger C; Qiao L
Cancer Gene Ther; 1997; 4(6):377-82. PubMed ID: 9408608
[TBL] [Abstract][Full Text] [Related]
4. Effects of retinoic acid combined with irradiation on the expression of major histocompatibility complex molecules and adhesion/costimulation molecules ICAM-1 in human cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Hiserodt JC; Pecorelli S; Parham GP
Gynecol Oncol; 1998 Aug; 70(2):195-201. PubMed ID: 9740690
[TBL] [Abstract][Full Text] [Related]
5. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro.
Kaufmann AM; Gissmann L; Street D; Schreckenberger C; Hunter M; Qiao L
Cell Immunol; 1996 May; 169(2):246-51. PubMed ID: 8620552
[TBL] [Abstract][Full Text] [Related]
7. CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens.
Chan RC; Xie Y
Oncol Rep; 2004 Aug; 12(2):435-42. PubMed ID: 15254713
[TBL] [Abstract][Full Text] [Related]
8. [Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-alpha and/or cimetidine on the expression].
Wu XX; Mizutani Y; Kakehi Y; Nakamura E; Mitsumori K; Takahashi T; Terachi T; Okada Y; Yoshida O
Hinyokika Kiyo; 1998 Sep; 44(9):621-6. PubMed ID: 9805665
[TBL] [Abstract][Full Text] [Related]
9. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
10. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
11. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
12. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
13. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
Propper DJ; Chao D; Braybrooke JP; Bahl P; Thavasu P; Balkwill F; Turley H; Dobbs N; Gatter K; Talbot DC; Harris AL; Ganesan TS
Clin Cancer Res; 2003 Jan; 9(1):84-92. PubMed ID: 12538455
[TBL] [Abstract][Full Text] [Related]
14. Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1.
Usui Y; Okunuki Y; Hattori T; Takeuchi M; Kezuka T; Goto H; Usui M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4607-13. PubMed ID: 17003458
[TBL] [Abstract][Full Text] [Related]
15. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
16. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits proinflammatory factor-induced over-expression of class II MHC and B7 molecules in renal tubular epithelial cells.
Li H; Liu ZH; Dai CS; Liu D; Li LS
Acta Pharmacol Sin; 2002 Sep; 23(9):775-81. PubMed ID: 12230943
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
[TBL] [Abstract][Full Text] [Related]
19. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
20. Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody.
Zhao C; Morgan M; Haeryfar SM; Blay J; Hoskin DW
Cancer Immunol Immunother; 2003 Mar; 52(3):185-93. PubMed ID: 12649748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
